News

Bryan Dennison breaks down the purpose-built technology behind ClaimGuardRx and how its detect-and-respond design keeps manufacturers ahead of evolving diversion tactics.

Matt Turner shares how ClaimGuardRx is redefining patient affordability by turning claims data into a proactive defense against maximizers and accumulators.

Overhaul's Danny Ramon argues that quality and regulatory teams, not just logistics, need faster protocols and more accessible stability data, since stolen or compromised product that re-enters the supply chain through gray markets can ultimately reach patients.

Cencora's Ameer Ali explains why trading partners' systems, not the NDC-12 deadline itself, determine whether product keeps moving through the supply chain during the transition.

Ed Schoonveld examines the uncertainty surrounding President Trump's MFN drug pricing agreements, stalled GENEROUS, GLOBE and GUARD proposals, and their ripple effects on ex-US drug launches.

AI-native operating systems present new capabilities to improve pharma supply chain operations.

Cencora's Gregg Gorniak on where DSCSA trading partners find shared value in compliance investment, and where that alignment breaks down.

In this week's Pharma Pulse, nine more drugmakers join the MFN program, GoodRx adds a family plan, IPC formalizes its USave partnership, and CSafe expands its thermal cover offerings.

McKesson's Scott Mooney discusses the technical and operational challenges of DSCSA compliance, from linking ERP systems to EPCIS to recurring friction in 340B transaction data exchange.

Pharmacy directors are using the growing number of publicly visible drug prices as leverage, new research shows. Manufacturers need to be ready, before those prices become a negotiation tool.

The acquisition formalizes a nearly decade-old partnership as independent pharmacies lean on cooperatives to offset PBM reimbursement pressure and closures.

Cardinal Health's Liberty Dewey breaks down the NDC-12 transition timeline and the vendor, association and wholesaler support smaller pharmacies will need to get ready.

As loss-of-exclusivity events accelerate, generics and biosimilars are diverging into distinct business models, demanding different regulatory, IP, and market access strategies from manufacturers.

Cencora's Gregg Gorniak breaks down what separates basic DSCSA compliance from using it to streamline transactions and strengthen trading partnerships.

Nine more manufacturers join the MFN program, pairing new Medicaid pricing deals with $19.6B in U.S. manufacturing investment and API reserve donations.

Cencora's Ameer Ali explains how the shift to NDC-12 is reshaping supply chain systems and why readiness still varies widely across manufacturers.

HDA's Kala Shankle explains what a national licensure standard could mean for wholesale distributors and 3PLs, and why its success depends on how much state-level variation remains.

Alexis Cogswell of Inizio Medical explains how combining real-world data, AI analysis and HCP context is helping medical affairs teams move from retrospective reporting to actionable, real-time strategy.

Ahead of HDA's 2026 Traceability Seminar, Cencora's Gregg Gorniak explains how AI and RFID are being used to catch DSCSA data gaps before trucks reach the dock.

In this week's Pharma Pulse, new Medicaid pricing deals are rumored, employer GLP-1 pullback, and McKesson's $2.25B oncology buy.

As pharmaceutical companies scale their use of AI across drug safety operations, the Council for International Organizations of Medical Sciences Working Group XIV's now-published guidance sets the bar for what will be required for sustained system validation.

Cardinal Health's Michelle Britt discusses the policy changes needed to secure independent pharmacy's future, from state advocacy wins to giving pharmacists a seat at the table.

TrumpRx has topped 800 drugs since its February launch, but managed care skepticism over real patient savings persists.

Virtual care's pre- and postvisit windows offer pharma marketers a more targeted, attentive audience than physical waiting rooms, new research shows, and most brands aren't capitalizing on it yet.

Vikram Anand explains how connected pharmacovigilance systems improve HCP and patient experiences, and why predictive, AI-driven intake is the next frontier for manufacturers.

Health care's real challenge isn't more data, it's activation. Arcadia's Sandy Leonard on turning real-world evidence into point-of-care action.

Cardinal Health's Michelle Britt discusses how independent pharmacies are expanding clinical services and leaning on distributor partnerships to meet evolving patient and community needs.

AMCP's Adam Colborn discusses survey findings on TrumpRx's six-month performance, examining payer skepticism about pricing claims and pharmacy access hurdles for patients.